Semax vs Cerebrolysin
Synthetic ACTH fragment nootropic vs multi-peptide neurotrophic brain extract — comparing two established neuroprotective agents with different regulatory histories.
Last updated: 2026-03-08
Quick Comparison Table
| Category | Semax | Cerebrolysin |
|---|---|---|
| Structure | Synthetic heptapeptide (ACTH 4-10 analogue + Pro-Gly-Pro) | Multi-peptide complex from porcine brain |
| Primary Mechanism | BDNF/NGF upregulation, melanocortin pathway | Multi-neurotrophic factor mimetic |
| Administration | Intranasal drops | IV or IM injection |
| Approval Status | Approved in Russia/CIS (since 1994) | Approved in 40+ countries |
| Primary Indications | Stroke, cognitive enhancement, optic nerve atrophy | Stroke, TBI, Alzheimer's, vascular dementia |
| Convenience | Self-administered nasal drops | Requires IV/IM injection (clinical setting) |
| Evidence Base | Moderate — Russian clinical trials + Western preclinical | Extensive — 50+ international clinical trials |
| Side Effects | Very few — nasal irritation rare | Injection site reactions, headache, dizziness |
Mechanism of Action
Semax
Semax Mechanism:
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analogue of ACTH(4-10) with a C-terminal Pro-Gly-Pro extension that enhances stability and CNS penetration.
Key actions: 1. **BDNF upregulation** — Increases Brain-Derived Neurotrophic Factor expression by 2-4 fold 2. **NGF upregulation** — Stimulates Nerve Growth Factor production 3. **TrkB receptor activation** — Downstream BDNF signalling for neuroplasticity 4. **Dopaminergic modulation** — Enhances dopamine and serotonin turnover 5. **Anti-inflammatory** — Reduces neuroinflammation via IL-6 and TNF-α suppression
Semax does not bind melanocortin receptors despite its ACTH-derived structure — its nootropic effects are independent of the HPA axis.
Cerebrolysin
Cerebrolysin Mechanism:
A standardised multi-peptide preparation mimicking the activity of endogenous neurotrophic factors (BDNF, NGF, CNTF, GDNF).
Key actions: 1. **Multi-neurotrophic mimetic** — Acts on BDNF, NGF, CNTF, and GDNF pathways 2. **Neuroprotection** — Reduces excitotoxicity and calpain activation 3. **Neuroplasticity** — Promotes dendritic branching and LTP 4. **Anti-apoptotic** — Bcl-2 upregulation, caspase inhibition 5. **Neurogenesis** — Stimulates neural stem cell proliferation
Clinical Trial Evidence
Semax Clinical Studies
Design: Randomised controlled trial
Participants: 27 participants
1% semax significantly improves the total estimate of life quality due to the improvement of emotional state and motivation in MND patients with the maximal effect on day 10. This finding suggests that it is feasible to administer 1% semax in complex MND palliative therapy.
View study — PubMed 18379501Design: Clinical trial
Participants: 43 participants
Duration: 10 days
Early rehabilitation and administration of semax increase BDNF plasma level, speed functional recovery, and improve motor performance.
View study — PubMed 29798983Design: Clinical trial
Addition of semax to therapeutic complex in patients with diseases of the optic nerve had a favorable impact on the intensity and rate of recovery and improved the visual functions.
View study — PubMed 10741256Design: Clinical trial
Participants: 30 participants
It was established that including of Semax in combined intensive therapy of acute ischemic stroke had some influence on the rate of restoration of the damaged neurological functions in terms of increasing the regress of general cerebral and focal, especially motor disorders.
View study — PubMed 11517472Cerebrolysin Clinical Studies
Design: Meta-analysis
Participants: 294 participants
Cerebrolysin shows promise as a useful neuroprotective treatment in stroke care by dramatically improving functional recovery, reducing symptomatic intracranial bleeding, and lowering mortality in acute ischemic stroke patients when used in conjunction with mechanical thrombectomy.
View study — PubMed 41880098Design: Meta-analysis
Participants: 22,347 participants
One-hundred seventy-three trials were extracted (22,347 participants, four VCI categories, 91 interventions, 145 outcomes). Ginkgo biloba extracts showed large to moderate improvements in cognition (Cohen's d: 0.83, 95% CI: 0.00 to 1.67) and small to moderate improvements in functional outcomes (Cohen's d: 0.50, 95% CI: 0.25 to 0.75).
View study — PubMed 41198594Design: Meta-analysis
Our study demonstrated that AChE inhibitors, Ginkgo biloba, and cerebrolysin are the optimum cognitive and activities of daily living medication for patients with AD.
View study — PubMed 34924395Design: Meta-analysis
Participants: 185 participants
Duration: 10 days
A total 185 patients underwent meta-analysis (mean admission GCS = 10.3, mean age = 45.3, and mean Baseline Prognostic Risk Score = 2.8).
View study — PubMed 33620612Benefits Comparison
Semax Unique Benefits
- Intranasal administration (no injection)
- Strong BDNF upregulation
- Cognitive enhancement in healthy individuals
- Approved since 1994 (30+ year track record in Russia)
- Minimal side effects
Shared Benefits
- Neuroprotection in stroke
- BDNF pathway enhancement
- Neuroplasticity promotion
- Clinical approval in multiple countries
- Well-tolerated safety profiles
Cerebrolysin Unique Benefits
- Larger international clinical trial database
- Multi-neurotrophic pathway activation
- Approved in 40+ countries
- Proven in stroke, TBI, and multiple dementias
- Meta-analysis confirmed efficacy
Research & Evidence
Semax Research
Semax has been extensively studied in Russian clinical trials since the early 1990s and has been an approved medication since 1994. Western preclinical studies have confirmed its BDNF-upregulating and neuroprotective properties. However, it has not undergone FDA/EMA regulatory evaluation or large-scale Western clinical trials.
Cerebrolysin Research
Cerebrolysin has the larger international evidence base — 50+ clinical trials including the CASTA stroke trial (1,070 patients), E-ADI Alzheimer's trial, and multiple meta-analyses. It is approved in 40+ countries, though not in the US or UK.
Head-to-Head Analysis
Direct Comparison:
Both are used clinically for stroke recovery in their respective approved markets, but no head-to-head trial exists.
Administration Advantage: Semax's intranasal delivery is a major practical advantage — self-administered, painless, and convenient. Cerebrolysin requires IV/IM injection in clinical settings.
Mechanism Overlap: Both upregulate BDNF pathways, but through different mechanisms. Semax stimulates endogenous BDNF production; Cerebrolysin provides exogenous BDNF-like peptide fragments. Both promote neuroplasticity and neuroprotection.
Evidence Scale: Cerebrolysin has more international clinical trial data. Semax's evidence is primarily from Russian research institutions, though it has been approved and used clinically in Russia since 1994.
Protocol Comparison
Semax Protocol
Semax Approved Protocols (Russia):
Cognitive Enhancement: 200-600mcg intranasal, 2-3 times daily. Cycles of 10-30 days.
Acute Stroke: 6-12mg intranasal daily for 10 days.
Optic Nerve: 200mcg intranasal, 2-3 times daily for 30 days.
Routes: Intranasal drops only (0.1% or 1% solution).
Cerebrolysin Protocol
Cerebrolysin Clinical Protocols:
Stroke: 30ml IV daily for 10-21 days. Alzheimer's: 10-30ml IV daily for 20 days, repeat every 3-6 months. TBI: 30-50ml IV daily for 5-10 days.
Routes: IV infusion or IM injection.
Safety Profiles
Semax Safety
Semax Safety:
Exceptionally well-tolerated. 30+ years of clinical use in Russia. Rare side effects: mild nasal irritation. No systemic adverse effects reported. No hormonal effects despite ACTH-derived structure. No abuse potential or withdrawal. Safe in elderly and paediatric populations.
Cerebrolysin Safety
Cerebrolysin Safety:
Well-characterised over 30 years. Common: injection site reactions, headache, dizziness (mild). Rare: allergic reactions (animal-derived). Contraindicated in epilepsy. Theoretical prion risk (porcine brain-derived) — no cases reported.
The Verdict
Both are established neuroprotective agents with decades of clinical use — Semax since 1994 in Russia, Cerebrolysin in 40+ countries. Semax offers the practical advantage of intranasal self-administration and strong BDNF upregulation. Cerebrolysin offers broader neurotrophic coverage and a larger international clinical trial database. For accessibility and convenience, Semax is preferred. For severe neurological conditions (stroke, TBI, dementia) with clinical supervision, Cerebrolysin has more robust evidence. Both represent validated peptide approaches to neuroprotection.
Frequently Asked Questions
Conclusion
Semax and Cerebrolysin are two of the most established neuroprotective peptide therapies in clinical use globally. Semax's intranasal convenience, strong BDNF upregulation, and exceptional tolerability make it attractive for both clinical and cognitive enhancement applications. Cerebrolysin's broader neurotrophic coverage and larger international trial database make it the more validated choice for serious neurological conditions. Both demonstrate that peptide-based neuroprotection is a viable therapeutic strategy with decades of real-world evidence.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Semax nor Cerebrolysin is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.